IVF Drug Costs Slashed in White House-Pharma Partnership

BOSTON, MA – February 06, 2026 – In a landmark move poised to reshape the landscape of fertility treatment in the United States, EMD Serono, in collaboration with the Trump Administration, has launched a new patient access program dramatically cutting the cost of its entire portfolio of in vitro fertilization (IVF) medications. The initiative, which provides discounts of up to 84% on crucial drugs, offers a significant financial lifeline to the more than 10 million American women who struggle with infertility, many of whom face prohibitive out-of-pocket expenses.

The program, accessible through the administration's TrumpRx.gov portal and a new dedicated website, FertilityInstantSavings.com, is the direct result of a partnership fulfilling goals outlined in President Trump's February 2025 Executive Order, "Expanding Access to In Vitro Fertilization.” It aims to simplify access and provide immediate, substantial savings for patients paying for their own treatment.

"Behind every fertility treatment is a person's hope and dream. Each step and effort towards easing this burdensome journey makes a real impact for these patients," said Miguel Fernández Alcalde, President of EMD Serono, in a statement. "We care deeply about every patient we serve, and these new pathways to access our therapies reflect our belief that breakthrough science must reach the people who need it most."

A Lifeline for Aspiring Parents

For countless American families, the dream of having a child is often overshadowed by the staggering cost of fertility treatments. A single IVF cycle can cost upwards of $20,000, and medications alone can account for thousands of dollars. Since many health insurance plans offer little to no coverage for these treatments, the financial burden falls squarely on patients, forcing many into debt or to abandon their journey to parenthood altogether.

The new EMD Serono program directly confronts this barrier. It provides a single coupon that covers the company's full suite of core IVF therapies, including Gonal-f® (follitropin alfa), Ovidrel® (choriogonadotropin alfa), and Cetrotide® (cetrorelix acetate). According to the administration, the discounts can save patients more than $2,000 per treatment cycle on average. One key drug, Gonal-f, could see a discount of over 796%, with even deeper discounts available for women below certain income thresholds.

Unlike many patient assistance programs that require extensive applications and income verification, the Fertility Instant Savings platform is designed for immediate use. Patients with a valid prescription who are paying out-of-pocket can obtain a discount code from the website and use it at participating pharmacies. This streamlined process is a significant departure from EMD Serono's existing needs-based programs like Compassionate Care, offering a new, accessible option for a broader range of patients, including those who may not qualify for traditional assistance but still struggle with the high costs.

Health service providers are already integrating the program. Cigna's Evernorth, for example, is partnering with TrumpRx to dispense EMD Serono's discounted fertility medications, signaling a rapid integration into the healthcare supply chain.

Policy Meets Pharma in a High-Stakes Partnership

This initiative is more than a corporate discount program; it is a centerpiece of a public-private partnership aimed at addressing national health priorities. The collaboration stems from the White House's 2025 Executive Order on IVF, which called for federal support to increase affordable access to fertility treatments. The agreement, announced in October 2025, represents a direct fulfillment of that policy directive.

The partnership structure includes unique incentives. In exchange for providing these deep discounts and investing in U.S.-based biopharmaceutical manufacturing and research, EMD Serono is set to receive tariff relief from the administration. This model highlights a strategic approach to lowering drug prices by aligning government policy with corporate action.

EMD Serono is not alone in this new landscape. The TrumpRx.gov portal features similar "most-favored-nation" pricing deals with other pharmaceutical giants, including AstraZeneca, Eli Lilly, and Novo Nordisk, covering a range of medications. The platform functions as a price-display portal, directing consumers to manufacturer websites to obtain coupons for cash-pay purchases.

While the program offers clear benefits, particularly for uninsured or underinsured patients, some experts note potential drawbacks of the broader cash-only model. Purchases made through TrumpRx typically do not count toward insurance deductibles or out-of-pocket maximums. However, this is less of a concern in the context of IVF, where insurance coverage is notoriously sparse. For the vast majority of fertility patients paying entirely out-of-pocket for their medications, the direct, upfront savings represent a crucial and unambiguous benefit.

Beyond Discounts: A Glimpse into the Future of Fertility Treatment

While immediate cost savings are grabbing headlines, a less visible but equally significant part of the agreement points to the future of fertility science in the U.S. As part of the initiative, EMD Serono received one of the first-ever Commissioner's National Priority Vouchers (CNPV) from the Food and Drug Administration (FDA) for its product Pergoveris® (follitropin alfa/lutropin alfa).

This voucher is part of a new FDA pilot program designed to radically expedite the review of drugs that address a U.S. health crisis and contribute to domestic manufacturing. The CNPV can slash the typical FDA review timeline from 10-12 months down to as little as one or two months.

Pergoveris, which is already available in many countries outside the U.S., is a potential therapeutic option for women with complex fertility issues who may benefit from concurrent therapy with both follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Its expedited path to the U.S. market could introduce new competition and, more importantly, provide a vital new option for patients who have not found success with existing protocols.

The selection of Pergoveris as one of the first products for this priority review underscores the administration's focus on fertility as a critical national health issue. This dual-pronged approach—addressing both the immediate affordability of existing drugs and accelerating the approval of new therapeutic innovations—signals a comprehensive strategy. For EMD Serono, a company whose science was instrumental in the birth of the first IVF baby in the U.S., this new chapter reinforces its long-standing role in helping families achieve the dream of having a child.